Related Experiment Video
Updated: May 25, 2026
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Treatment with targeted vesicular stomatitis virus generates therapeutic multifunctional anti-tumor memory CD4 T
Y Gao1, P Whitaker-Dowling, J A Griffin
1Department of Pediatrics, University of Pittsburgh, Pittsburgh, PA 15224, USA.
Abstract:
A generally applicable, easy-to-use method of focusing a patient's immune system to eradicate or prevent cancer has been elusive. We are attempting to develop a targeted virus to accomplish these aims. We previously created a recombinant replicating vesicular stomatitis virus (VSV) that preferentially infected Her2/neu expressing breast cancer cells and showed therapeutic efficacy in an implanted Balb/c mouse tumor model. The current work shows that this therapy generated therapeutic anti-tumor CD4 T cells against multiple tumor antigens. CD4 T cells transferred directly from cured donor mice could eradicate established tumors in host mice. T cells were transferred directly from donor mice and were not stimulated ex vivo. Both tumors that expressed Her2/neu and those that did not were cured by transferred T cells. Analysis of cytokines secreted by anti-tumor memory CD4 T cells displayed a multifunctional pattern with high levels of interferon-γ, interleukin (IL)-4 and IL-17. Anti-tumor memory CD4 T cells traveled to the mesenteric lymph nodes and were activated there. Treatment with targeted recombinant replicating VSV is a potent immune adjuvant that generates therapeutic, multifunctional anti-tumor memory CD4 T cells that recognize multiple tumor antigens. Immunity elicited by viral therapy is independent of host major histocompatibility complex or knowledge of tumor antigens. Virus-induced tumor immunity could have great benefit in the prevention and treatment of tumor metastases.
Insights
A novel virus therapy effectively trains the immune system to fight cancer by generating potent CD4 T cells. This approach shows promise for preventing and treating various tumors, including metastases.
Area of Science:
- Oncolytic Virology
- Immunotherapy
- Cancer Research
Background:
- Developing effective cancer immunotherapies that can be broadly applied remains a significant challenge.
- Targeted viral therapies offer a promising strategy for stimulating anti-tumor immune responses.
Purpose of the Study:
- To evaluate a recombinant replicating vesicular stomatitis virus (VSV) as a cancer immunotherapy.
- To investigate the generation and function of anti-tumor CD4 T cells induced by VSV therapy.
Main Methods:
- Development of a recombinant VSV engineered to target Her2/neu expressing breast cancer cells.
- Administration of VSV therapy to tumor-bearing mice and assessment of tumor eradication.
- Transfer of CD4 T cells from cured mice to naive hosts to assess therapeutic potential.
- Analysis of cytokine profiles and immune cell trafficking in response to VSV treatment.
Main Results:
- VSV therapy eradicated established tumors, including those not expressing the target antigen Her2/neu.
- Therapy induced multifunctional CD4 T cells producing interferon-γ, interleukin-4, and interleukin-17.
- Transferred CD4 T cells from cured mice conferred complete tumor protection.
- Anti-tumor CD4 T cells trafficked to lymph nodes and exhibited activation.
Conclusions:
- Targeted recombinant VSV acts as a potent immune adjuvant, generating therapeutic anti-tumor CD4 T cells.
- This viral therapy elicits broad anti-tumor immunity independent of host MHC or known tumor antigens.
- VSV-induced immunity holds significant potential for preventing and treating cancer, including metastases.
More Related Videos
08:52Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
Published on: May 27, 2011
08:10Simultaneous Quantification of Anti-vector and Anti-transgene-Specific CD8+ T Cells Via MHC I Tetramer Staining After Vaccination with a Viral Vector
Published on: November 28, 2018
Related Concept Videos
01:27Tumor Immunotherapy
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:29Immune Response Against Viral Pathogens
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
01:21Vaccines